Justice Enters Two Qui Tam Suits Over Off-Label Promotion

The Justice Department is intervening in two whistle-blower suits filed against Johnson & Johnson and its Scios unit by former sales managers for allegedly promoting the heart drug Natrecor for off-label uses. The suits, which were filed in 2005, allege the defendants marketed Natrecor (nesiritide recombinant) for serial infusions in the outpatient setting, which is not an approved indication. Justice intends to file its own complaint and serve it by June 11, according to court documents.
Washington Drug Letter